The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: Occurrence in high-risk non-Ashkenazi Jews

Genetic Testing

Volumn 10, Issue 3, 2006, Pages 200-207

  Kaufman, Bella ^a   Laitman, Yael ^a   Carvalho, Marcelo A ^b   Edelman, Limor ^a   Menachem, Tal Distelman ^a   Zidan, Jamal ^c   Monteiro, Alvaro N ^b   Friedman, Eitan ^a,d  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Rebecca Sieff Government Hospital   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; PROLINE; THREONINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ETHNIC DIFFERENCE; FAMILY ASSESSMENT; FEMALE; FOUNDER EFFECT; GENE ACTIVITY; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; IRAN; IRAQ; JEW; MAJOR CLINICAL STUDY; MAMMAL CELL; MUTATIONAL ANALYSIS; NONHUMAN; NORTH AFRICA; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATHOGENICITY; PREVALENCE; REPORTER GENE; TUMOR SUPPRESSOR GENE; YEAST CELL; YEMEN;

ADULT; AGED; ALANINE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JEWS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEDIGREE; PROLINE; SEQUENCE DELETION; THREONINE;

MAMMALIA;

EID: 33845192319     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2006.10.200     Document Type: Article

References (30)

1. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Gail A, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505-514.
2. Berman DB, Wagner-Costalas J, Schultz DC, Lynch DC, Daly M, Godwin AK (1996) Two distinct origins of a common mutation in breast-Ovarian cancer families: A genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 58:1166-1176.
3. BIC database: http://www.nhgn.nih.gov/Intramural_research/Lab_transfer/ Bic/Member/index.html
4. Bonne-Tamir B, Karlin S, Kenett R (1979) Analysis of genetic data on Jewish populations. I. Historical background, demographic features, and genetic markers. Am J Hum Genet 31:324-340.
5. Brent R, Ptashne M (1985) A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor. Cell 43(3 Pt 2):729-736.
6. Bruchim Bar-Sade R, Theodor L, Gak E, Kruglikova A, Hirsch-Yechezkel G, Modan B, Kuperstein G, Seligsohn U, Rechavi G, Friedman E (1997) Could the 185delAG BRCA1 mutation be an ancient Jewish-mutation. Eur J Hum Genet 5:413-416.
7. Bruchim Bar-Sade R, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, Theodor L, Novikov I, Gershoni-Baruch R, Risel S, Papa MZ, Ben-Baruch G, Friedman E (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim. Hum Mol Genet 7:801-806.
8. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, Boyd J, Lubin MB, Deshano ML, Brody LC, Collins FS, Weber BL (1994) Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 8:387-398.
9. Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, De La HM, Salazar R, Vega A, Campos B, Rodriguez-Lopez R, Velasco E, Chaves J, az-Rubio E, Jesus CJ, Torres M, Esteban E, Cervantes A, Alonso C, San Roman JM, Gonzalez-Sarmiento R, Miner C, Carracedo A, Eugenia AM, Caldes T, Benitez J, Baiget M. (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301-312.
10. Easton DF, Bishop DT, Ford D, Cockford GP, and the Breast Cancer Linkage Consortium (1993) Genetic linkage analysis in familial breast and ovarian cancer. Am J Hum Genet 52:718-722.
11. Elimelech A, Sagi M, Shochat C, Korem S, Levi D, Kaduri L, Nissan A, Peretz T, Bercovich D (2005) Mutations screening in BRCA1/2 genes in non-Ashkenazi women. The American Society of Human Genetics 55th annual meeting, abstract #470, p.106.
12. Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E (2004) The 100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Fam Cancer 3:11-14.
13. Gilad S, Bar-Shira A, Harnik R, Shkedy D, Ziv Y, Khosravi R, Brown K, Vanagaite L, Xu G, Frydman M, Lavin MF, Hill D, Tagle DA, Shiloh Y (1996) Ataxia-telangiectasia: founder effect among north African Jews. Hum Mol Genet 5:2033-2037.
14. Hall JM, Lee MK, Newman B, Morrow J E, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689.
15. Hayes F, Cayanan C, Barilla D, Monteiro AN (2000) Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res 60:2411-2418.
16. Higuchi R, Innis MA, Gelfand DH, Sninsky JJ, White TJ (2003) PCR Protocols: A guide to methods and applications. Academic Press, San Diego, California: pp 177-183.
17. Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, Stadler J, Gutman H, Abeliovich D (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63:272-274.
18. Lynch HT, Watson P, Tinley S, Snyder C, Durham C, Lynch J, Kirnarsky Y, Serova O, Lenoir G, Lerman C, Narod SA (1999) An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet 109:91-98.
19. Martinez-Ferrandis JI, Vega A, Chirivella I, Marin-Garcia P, Insa A, Lluch A, Carracedo A, Chaves FJ, Garcia-Conde J, Cervantes A, Armengod ME (2003) Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations. Hum Mutat 22:417-418.
20. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harsman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Pelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wessman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71.
21. Nebel A, Filon D, Brinkmann B, Majumder PP, Faerman M, Oppenheim A (2001) The Y chromosome pool of Jews as part of the genetic landscape of the Middle East. Am J Hum Genet 69:1095-1112.
22. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58:271-280.
23. Ostrer H (2001) A genetic profile of contemporary Jewish populations. Nat Rev Genet 2:891-898.
24. Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, Caldes T, De La HM, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN (2005) Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 42:138-146.
25. Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM. (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43:24-29.
26. Shinar Y, Livneh A, Villa Y, Pinhasov A, Zeitoun I, Kogan A, Achiron A (2003) Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. Genes Immun 4:197-203.
27. Shiri -Sverdlov R, Gershoni Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bruchim Bar-Sade R, Chetrit A, Rizel S, Modan B, Friedman E (2001a) The Tyr978x BRCA1 mutation in non-Ashkenazi jews: occurrence in high risk families, general population and unselected vvarian cancer patients. Commun Genet 4:50-55.
28. Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E (2001b) Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat 16:491-501.
29. Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013-1020.
30. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangione J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Harnoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Fucenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Surr NK, Ponder BAJ, Eeles R, Peto J, Deville P, Corneliss C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792.